Sep 2, 2021 · MCL1 (myeloid cell leukemia-1) is a widely recognized pro-survival member of the Bcl-2 (B-cell lymphoma protein 2) family and a promising target for cancer therapy. While the role MCL1...

The BCL-2 family has four main functions: inhibitory effects (BCL-2, BCL-Xl, BCL-W, BCL2-A1, and MCL-1), activation (BIM and PUMA), effector (BAX and BAK), and sensitization (NOXA). BCL-2 and its closest homolog promote cell survival …

Jan 15, 1997 · Mcl-1 is a member of the Bcl-2 family that was identified based on increased expression in myeloblastic leukemia cells undergoing differentiation. Mcl-1 was previously found to be similar to Bcl-2 in causing a delay in apoptotic cell death in Chinese hamster ovary cells.

Apr 24, 2019 · Our data show for the first time that therapies targeting specific combinations of BCL-2 pro-survival proteins, namely MCL-1 plus BCL-XL and MCL-1 plus BCL-2, could have significant...

The loss of MCL1 has a more dramatic impact than the loss of any other anti-apoptotic member of the Bcl-2 family. Loss of the Mcl-1 gene results in embryo death when the embryo is only around 3.5 days old, before it has even implanted. Conditional deletion of Mcl-1 depletes a wide variety of cells, including hematopoietic stem cells, ...

4 days ago · BCL-2 family members also contribute to autophagy regulation; BCL-2 and MCL-1, for instance, inhibit autophagy, balancing cell survival during nutrient scarcity . These non-apoptotic functions of ...

MCL-1S a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem. 2000;275:25255–25261. doi: 10.1074/jbc.M909826199.

Mar 1, 2019 · Myeloid Cell Leukemia 1 (MCL-1) was cloned from a human myeloid leukemia cell line during TPA-induced differentiation (Kozopas, Yang, Buchan, Zhou, & Craig, 1993). Based on the sequence homology, it belongs to the Bcl-2 family of anti-apoptotic genes, such as Bcl-2, Bcl-2 L10, Bcl-W and Bcl-xL (Kelekar & Thompson, 1998).

Although the BCL-2 inhibitor Venetoclax is in clinical use and inhibitors of BCL-XL and MCL-1 are undergoing clinical trials, several questions remain on whether therapeutic windows can be achieved and what other agents should be used in combination with BH3 mimetics to achieve optimal therapeutic impact for cancer therapy. Finally, the control ...

Combined inhibition of BCL-2 and MCL-1 synergistically induces apoptosis in primary acute myeloid leukemia (AML) cells and AML stem/progenitor cells under mesenchymal stromal cell co-culture conditions.